165 related articles for article (PubMed ID: 38267057)
1. Characteristics of MicroRNA Expression Depending on the Presence or Absence of Meningioma in Patients with Neurofibromatosis Type 2: A Secondary Analysis.
Imura T; Mitsuhara T; Horie N
Neurol Med Chir (Tokyo); 2024 Mar; 64(3):116-122. PubMed ID: 38267057
[TBL] [Abstract][Full Text] [Related]
2. Distinctive MicroRNA Profiles in Serum of Patients with Neurofibromatosis Type 2: A Bioinformatic Exploratory Study.
Imura T; Shimizu K; Mitsuhara T
World Neurosurg; 2022 Aug; 164():e127-e133. PubMed ID: 35436578
[TBL] [Abstract][Full Text] [Related]
3. Cases of Mixed Schwannoma-Meningioma With and Without Neurofibromatosis 2 with Emphasis on Tumorigenesis.
Rajeswarie RT; Mallik D; Rudrappa S; Gopal S
Int J Surg Pathol; 2024 May; 32(3):511-514. PubMed ID: 37487199
[TBL] [Abstract][Full Text] [Related]
4. Validation of a scoring system to evaluate the risk of rapid growth of intracranial meningiomas in neurofibromatosis type 2 patients.
Abi Jaoude S; Peyre M; Degos V; Goutagny S; Parfait B; Kalamarides M
J Neurosurg; 2020 May; 134(5):1377-1385. PubMed ID: 32442973
[TBL] [Abstract][Full Text] [Related]
5. Familial meningioma is not allelic to neurofibromatosis 2.
Pulst SM; Rouleau GA; Marineau C; Fain P; Sieb JP
Neurology; 1993 Oct; 43(10):2096-8. PubMed ID: 8413972
[TBL] [Abstract][Full Text] [Related]
6. Meningiomas in patients with neurofibromatosis type 2 predominantly comprise 'immunogenic subtype' tumours characterised by macrophage infiltration.
Teranishi Y; Miyawaki S; Nakatochi M; Okano A; Ohara K; Hongo H; Ishigami D; Sakai Y; Shimada D; Takayanagi S; Ikemura M; Komura D; Katoh H; Mitsui J; Morishita S; Ushiku T; Ishikawa S; Nakatomi H; Saito N
Acta Neuropathol Commun; 2023 Sep; 11(1):156. PubMed ID: 37752594
[TBL] [Abstract][Full Text] [Related]
7. Identification of a Transcription Factor-microRNA-Gene Coregulation Network in Meningioma through a Bioinformatic Analysis.
Wang J; Liang Y; Yang H; Wu JH
Biomed Res Int; 2020; 2020():6353814. PubMed ID: 32832554
[TBL] [Abstract][Full Text] [Related]
8. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas.
Antinheimo J; Sankila R; Carpén O; Pukkala E; Sainio M; Jääskeläinen J
Neurology; 2000 Jan; 54(1):71-6. PubMed ID: 10636128
[TBL] [Abstract][Full Text] [Related]
9. The role and regulatory mechanism of IL-1β on the methylation of the NF2 gene in benign meningiomas and leptomeninges.
Wang B; Cui Z; Zhong Z; Sun Y; Yang GY; Sun Q; Bian L
Mol Carcinog; 2016 Dec; 55(12):2268-2277. PubMed ID: 26840621
[TBL] [Abstract][Full Text] [Related]
10. Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset.
Smith MJ; Higgs JE; Bowers NL; Halliday D; Paterson J; Gillespie J; Huson SM; Freeman SR; Lloyd S; Rutherford SA; King AT; Wallace AJ; Ramsden RT; Evans DG
J Med Genet; 2011 Apr; 48(4):261-5. PubMed ID: 21278391
[TBL] [Abstract][Full Text] [Related]
11. Germline deletion in a neurofibromatosis type 2 kindred inactivates the NF2 gene and a candidate meningioma locus.
Sanson M; Marineau C; Desmaze C; Lutchman M; Ruttledge M; Baron C; Narod S; Delattre O; Lenoir G; Thomas G
Hum Mol Genet; 1993 Aug; 2(8):1215-20. PubMed ID: 8401504
[TBL] [Abstract][Full Text] [Related]
12. Molecular genetic investigation of the neurofibromatosis type 2 tumor suppressor gene in sporadic meningioma.
Harada T; Irving RM; Xuereb JH; Barton DE; Hardy DG; Moffat DA; Maher ER
J Neurosurg; 1996 May; 84(5):847-51. PubMed ID: 8622160
[TBL] [Abstract][Full Text] [Related]
13. Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis.
Bachir S; Shah S; Shapiro S; Koehler A; Mahammedi A; Samy RN; Zuccarello M; Schorry E; Sengupta S
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33445724
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive genetic and epigenetic analysis of sporadic meningioma for macro-mutations on 22q and micro-mutations within the NF2 locus.
Hansson CM; Buckley PG; Grigelioniene G; Piotrowski A; Hellström AR; Mantripragada K; Jarbo C; Mathiesen T; Dumanski JP
BMC Genomics; 2007 Jan; 8():16. PubMed ID: 17222329
[TBL] [Abstract][Full Text] [Related]
15. Molecular alterations in the neurofibromatosis type 2 gene and its protein rarely occurring in meningothelial meningiomas.
Evans JJ; Jeun SS; Lee JH; Harwalkar JA; Shoshan Y; Cowell JK; Golubic M
J Neurosurg; 2001 Jan; 94(1):111-7. PubMed ID: 11147878
[TBL] [Abstract][Full Text] [Related]
16. A patient with mosaic neurofibromatosis type 2 presenting with early onset meningioma.
Chu YW; Cheuk DK; Chung BH; Bowers NL; Ha SY; Chiang AK; Chan GC
BMJ Case Rep; 2014 Nov; 2014():. PubMed ID: 25406210
[TBL] [Abstract][Full Text] [Related]
17. Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis.
Louvrier C; Pasmant E; Briand-Suleau A; Cohen J; Nitschké P; Nectoux J; Orhant L; Zordan C; Goizet C; Goutagny S; Lallemand D; Vidaud M; Vidaud D; Kalamarides M; Parfait B
Neuro Oncol; 2018 Jun; 20(7):917-929. PubMed ID: 29409008
[TBL] [Abstract][Full Text] [Related]
18. A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.
Beauchamp RL; James MF; DeSouza PA; Wagh V; Zhao WN; Jordan JT; Stemmer-Rachamimov A; Plotkin SR; Gusella JF; Haggarty SJ; Ramesh V
Oncotarget; 2015 Jul; 6(19):16981-97. PubMed ID: 26219339
[TBL] [Abstract][Full Text] [Related]
19. First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.
Dewan R; Pemov A; Dutra AS; Pak ED; Edwards NA; Ray-Chaudhury A; Hansen NF; Chandrasekharappa SC; Mullikin JC; Asthagiri AR; ; Heiss JD; Stewart DR; Germanwala AV
BMC Cancer; 2017 Feb; 17(1):127. PubMed ID: 28193203
[TBL] [Abstract][Full Text] [Related]
20. Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.
Kalamarides M; Stemmer-Rachamimov AO; Takahashi M; Han ZY; Chareyre F; Niwa-Kawakita M; Black PM; Carroll RS; Giovannini M
Brain Pathol; 2008 Jan; 18(1):62-70. PubMed ID: 17924978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
